Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Cytomegalovirus Infection

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    December 2025
  1. NATORI Y, Sester M
    The role of CMV-specific cellular immunity in transplant recipients with letermovir prophylaxis: to be determined.
    Clin Infect Dis. 2025 Dec 1:ciaf633. doi: 10.1093.
    PubMed    


  2. LIMAYE AP, Crespo M, Kamar N, Humar A, et al
    Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-seronegative kidney transplant recipients.
    Clin Infect Dis. 2025 Dec 1:ciaf632. doi: 10.1093.
    PubMed     Abstract available


  3. PAPANICOLAOU GA, Dadwal SS, Ariza-Heredia EJ, Chiusolo P, et al
    An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.
    Clin Infect Dis. 2025 Dec 1:ciaf646. doi: 10.1093.
    PubMed     Abstract available


    August 2025
  4. FOURGEAUD J, Barry M, Bourgon N, Veyrenche N, et al
    Cytomegalovirus vertical transmission rate according to IgG avidity value and valacyclovir treatment of maternal primary infection in the first trimester of pregnancy.
    Clin Infect Dis. 2025 Aug 6:ciaf437. doi: 10.1093.
    PubMed     Abstract available


    July 2025
  5. WANG L, Huang J, Jiang C, Huang M, et al
    Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients.
    Clin Infect Dis. 2025 Jul 24:ciaf410. doi: 10.1093.
    PubMed     Abstract available


    May 2025
  6. FUNG JST, Wright RC, Bharaj DK, Alghamdi A, et al
    Virus-specific T-cell therapy for prophylaxis and treatment of cytomegalovirus infections after transplantation: a scoping review.
    Clin Infect Dis. 2025 May 6:ciaf232. doi: 10.1093.
    PubMed     Abstract available


    March 2025
  7. VELAPHI S, Madewell ZJ, Tippett-Barr B, Blau DM, et al
    Investigating the role of cytomegalovirus as a cause of stillbirths and child deaths in low and middle-income countries through postmortem minimally invasive tissue sampling.
    Clin Infect Dis. 2025 Mar 10:ciaf098. doi: 10.1093.
    PubMed     Abstract available


    November 2024
  8. HELDMAN MR, Boeckh MJ, Limaye AP
    Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation.
    Clin Infect Dis. 2024 Nov 4:ciae535. doi: 10.1093.
    PubMed     Abstract available


    August 2024

  9. Correction to: Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
    Clin Infect Dis. 2024 Aug 2:ciae356. doi: 10.1093.
    PubMed    


    July 2024
  10. CUELLAR-RODRIGUEZ JM, van Duin D
    Cytomegalovirus Disease: Fine-Tuning Clinical Trial Enrollment and Standardization.
    Clin Infect Dis. 2024 Jul 29:ciae319. doi: 10.1093.
    PubMed    


  11. LJUNGMAN P, Chemaly RF, Khawaya F, Alain S, et al
    Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
    Clin Infect Dis. 2024 Jul 23:ciae321. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  12. HAMMOND SP, Little JS
    How much does cytomegalovirus viremia matter after chimeric antigen receptor T-cell therapy?
    Clin Infect Dis. 2024 Feb 2:ciae053. doi: 10.1093.
    PubMed    


  13. KAMPOURI E, Boeckh MJ, Hill JA
    Understanding the clinical significance of cytomegalovirus viremia after chimeric antigen receptor T-cell therapy: Should we be treating a value?
    Clin Infect Dis. 2024 Feb 2:ciae030. doi: 10.1093.
    PubMed    


    January 2024
  14. YATES TA, Halliday N
    Re: Association of CMV DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy (PET) and Antiviral Prophylaxis (AP) for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative (D+R-) Liver Transplant Reci
    Clin Infect Dis. 2024 Jan 9:ciae004. doi: 10.1093.
    PubMed    


  15. KUMAR L, Dasgupta S, Murray-Krezan C, Singh N, et al
    Response to Yates and Halliday regarding CMV DNAemia and time-to-mortality in a Randomized Trial of PET vs AP in CMV D+R-Liver Transplant Recipients.
    Clin Infect Dis. 2024 Jan 8:ciae005. doi: 10.1093.
    PubMed    


    November 2023
  16. PAPANICOLAOU GA, Avery RK, Cordonnier C, Duarte RF, et al
    Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir with Valganciclovir.
    Clin Infect Dis. 2023 Nov 30:ciad709. doi: 10.1093.
    PubMed     Abstract available


  17. KAMPOURI E, Ibrahimi SS, Xie H, Wong ER, et al
    CMV Reactivation and CMV-Specific Cell-Mediated Immunity after Chimeric Antigen Receptor T-Cell Therapy.
    Clin Infect Dis. 2023 Nov 17:ciad708. doi: 10.1093.
    PubMed     Abstract available


    October 2023
  18. KUMAR L, Dasgupta S, Murray-Krezan C, Singh N, et al
    Association of CMV DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy (PET) and Antiviral Prophylaxis (AP) for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative (D+R-) Liver Transplant Recipien
    Clin Infect Dis. 2023 Oct 20:ciad643. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  19. MANUEL O, Laager M, Hirzel C, Neofytos D, et al
    Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial.
    Clin Infect Dis. 2023 Sep 22:ciad575. doi: 10.1093.
    PubMed     Abstract available


  20. PORTILLO V, Masouridi-Levrat S, Royston L, Yerly S, et al
    Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients.
    Clin Infect Dis. 2023 Sep 15:ciad550. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  21. AMIR J, Chodick G, Pardo J
    Revised protocol for secondary prevention of congenital cytomegalovirus infection with valaciclovir following infection in early pregnancy.
    Clin Infect Dis. 2023 May 9:ciad230. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  22. PLOTKIN SA
    Can We Prevent Congenital Infection By Cytomegalovirus?
    Clin Infect Dis. 2023 Mar 28:ciad179. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cytomegalovirus Infection is free of charge.